IL133907A0 - Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor - Google Patents

Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor

Info

Publication number
IL133907A0
IL133907A0 IL13390798A IL13390798A IL133907A0 IL 133907 A0 IL133907 A0 IL 133907A0 IL 13390798 A IL13390798 A IL 13390798A IL 13390798 A IL13390798 A IL 13390798A IL 133907 A0 IL133907 A0 IL 133907A0
Authority
IL
Israel
Prior art keywords
glucocidase
thiazolidinedione
diabetes
inhibitor
alpha
Prior art date
Application number
IL13390798A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of IL133907A0 publication Critical patent/IL133907A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
IL13390798A 1997-07-18 1998-07-16 Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor IL133907A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9715298A GB9715298D0 (en) 1997-07-18 1997-07-18 Novel method of treatment
PCT/GB1998/002112 WO1999003478A1 (fr) 1997-07-18 1998-07-16 Traitement du diabete avec du thiazolidinedione, un secretagogue d'insuline et un inhibiteur d'alpha glucosidase

Publications (1)

Publication Number Publication Date
IL133907A0 true IL133907A0 (en) 2001-04-30

Family

ID=10816170

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13390798A IL133907A0 (en) 1997-07-18 1998-07-16 Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor

Country Status (27)

Country Link
EP (1) EP1001784A1 (fr)
JP (1) JP2001510160A (fr)
KR (1) KR20010021952A (fr)
CN (1) CN1263467A (fr)
AP (1) AP2000001735A0 (fr)
AR (2) AR016350A1 (fr)
AU (1) AU8449098A (fr)
BG (1) BG104062A (fr)
BR (1) BR9810292A (fr)
CA (1) CA2297133A1 (fr)
CO (1) CO4940489A1 (fr)
DZ (1) DZ2563A1 (fr)
EA (1) EA200000140A1 (fr)
GB (1) GB9715298D0 (fr)
HU (1) HUP0003626A3 (fr)
ID (1) ID23804A (fr)
IL (1) IL133907A0 (fr)
MA (1) MA24608A1 (fr)
NO (1) NO20000230L (fr)
OA (1) OA11312A (fr)
PE (1) PE99499A1 (fr)
PL (1) PL338140A1 (fr)
SK (1) SK612000A3 (fr)
TR (1) TR200000133T2 (fr)
UY (1) UY25101A1 (fr)
WO (1) WO1999003478A1 (fr)
ZA (1) ZA986364B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
USRE40876E1 (en) 1999-06-21 2009-08-18 Eli Lilly And Company Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagonlike peptide-1 and agonists thereof
PT1741446E (pt) * 2000-01-21 2008-05-09 Novartis Pharma Ag Combinações incluindo inibidores da dipeptidilpeptidase-iv e agentes anti-diabéticos
JP4917712B2 (ja) * 2000-02-24 2012-04-18 武田薬品工業株式会社 併用医薬
EP1295609A4 (fr) * 2000-02-24 2004-11-03 Takeda Chemical Industries Ltd Medicaments contenant des ingredients actifs combines
ATE508738T1 (de) 2001-01-12 2011-05-15 Sun Pharma Advanced Res Co Ltd System zur beabstandeten abgabe von arzneimitteln
FR2832930A1 (fr) * 2001-12-03 2003-06-06 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
MXPA06004639A (es) 2003-10-31 2006-06-27 Takeda Pharmaceutical Preparacion solida que comprende sensibilizador de insulina, secretagogo de insulina y ester de acidos grasos de polioxietileno sorbitano.
CN101103993B (zh) * 2006-07-14 2011-03-30 北京华安佛医药研究中心有限公司 降糖药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900435A (en) * 1991-08-26 1999-05-04 Pharmacia & Upjohn Company Composition, food product and uses of 3-guanidinopropionic acid
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
AP2000001735A0 (en) 2000-01-16
CN1263467A (zh) 2000-08-16
CA2297133A1 (fr) 1999-01-28
BR9810292A (pt) 2000-09-19
KR20010021952A (ko) 2001-03-15
TR200000133T2 (tr) 2000-09-21
AR019724A2 (es) 2002-03-13
EP1001784A1 (fr) 2000-05-24
EA200000140A1 (ru) 2000-06-26
NO20000230D0 (no) 2000-01-17
HUP0003626A2 (hu) 2001-05-28
PL338140A1 (en) 2000-09-25
MA24608A1 (fr) 1999-04-01
NO20000230L (no) 2000-01-17
BG104062A (en) 2000-11-30
ID23804A (id) 2000-05-11
OA11312A (en) 2003-10-24
AU8449098A (en) 1999-02-10
PE99499A1 (es) 1999-12-18
ZA986364B (en) 2000-01-17
AR016350A1 (es) 2001-07-04
WO1999003478A1 (fr) 1999-01-28
SK612000A3 (en) 2000-07-11
UY25101A1 (es) 2000-12-29
CO4940489A1 (es) 2000-07-24
JP2001510160A (ja) 2001-07-31
DZ2563A1 (fr) 2003-02-15
GB9715298D0 (en) 1997-09-24
HUP0003626A3 (en) 2001-12-28

Similar Documents

Publication Publication Date Title
AP9901719A0 (en) Treatment of diabetes with thiazolidinedione and metormin
HUP0002053A3 (en) Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
PL342517A1 (en) Methods of treating diabetes employing peptidic insulin analoques
HUP0203367A3 (en) Benzylidine-thiazolidinediones and analogues and their use in the treatment of diabetes
HUP0003876A3 (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
IL127219A0 (en) The use of insulin sensitivity enhancers for treatment of hyperuricemia and compositions containing insulin sensitivity enhancers for treating the same
IL134046A0 (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
HUP0300218A3 (en) Process for treatment of diabetes, employing combination of metformin and glyburide
ZA985546B (en) Treatment of insulin resistance.
PL343123A1 (en) Treatment of diabetes with rosiglitazone and insulin
ZA98647B (en) Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
IL133907A0 (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor
IL134045A0 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
AP9901717A0 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
PL337577A1 (en) Treatment of diabetes with thiazolydinone and alpha - glucosidaze inhibitor
HK1028551A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucosidase inhibitor
HUP0002668A3 (en) Treatment of diabetes with thiazolidinedione and metformin
HK1028198A (en) Treatment of diabetes with rosiglitazone and insulin
HUP0002669A3 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
HK1025263A (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
IL121656A0 (en) Diagnosis prevention and treatment of diabetes
GB9705041D0 (en) Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity